Today: 29 April 2026
Browse Category

NASDAQ:DYN 7 October 2025 - 4 January 2026

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

TuHURA Biosciences plunged 36.9% after announcing a $15.6 million direct offering with warrants, triggering heavy dilution concerns. Phreesia, Euda Health, SLM Corp, Virgin Galactic, and Gogo each fell more than 15%. Major indexes stayed mostly flat, with the Dow up 0.2% and the S&P 500 up 0.1% as traders awaited the Federal Reserve’s policy decision.
9 December 2025
··········
Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics shares jumped 14% to $23.20 by mid-afternoon Monday after the company reported its Phase 1/2 DELIVER trial in Duchenne muscular dystrophy met its primary endpoint. The stock touched an intraday high near $25.68 on volume over 2.5 million shares. Dyne plans to seek U.S. accelerated approval in 2026. The company reported $792 million in cash as of Q3 2025.
8 December 2025
·
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics shares jumped over 10% to around $14 after new trial data showed its lead therapy improved muscle function with no serious side effects. The stock is up about 75% in six months. Dyne’s Duchenne drug just received Orphan Drug status in Japan and positive analyst upgrades, with price targets averaging $34. The company ended June with $683.9 million in cash, extending its runway into 2027.
7 October 2025
·

Stock Market Today

  • Aurelia Metals and Top ASX Penny Stocks Highlighted Amid Market Downturn
    April 28, 2026, 11:58 PM EDT. The Australian share market faces a seventh day of decline amid inflation and interest rate concerns. Investors are eyeing ASX penny stocks for growth opportunities, including Aurelia Metals Limited (ASX:AMI), valued at A$474.15 million with earnings growth of 275.5% over the past year. Aurelia's financials show strong short-term assets and healthy cash flow covering debt, trading below estimated fair value. Other notable penny stocks include Nova Eye Medical and LaserBond. Caution is advised as some boards lack seasoned leadership. Despite overall market weakness, certain penny stocks offer potential value for risk-tolerant investors.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop